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GM604 regulates developmental
neurogenesis pathways and the expression
of genes associated with amyotrophic
lateral sclerosis
William R. Swindell1* , Krzysztof Bojanowski2, Mark S. Kindy3,4, Raymond M. W. Chau5 and Dorothy Ko5
Abstract
Background: Amyotrophic lateral sclerosis (ALS) is currently an incurable disease without highly effective
pharmacological treatments. The peptide drug GM604 (GM6 or Alirinetide) was developed as a candidate ALS
therapy, which has demonstrated safety and good drug-like properties with a favorable pharmacokinetic profile.
GM6 is hypothesized to bolster neuron survival through the multi-target regulation of developmental pathways,
but mechanisms of action are not fully understood.
Methods: This study used RNA-seq to evaluate transcriptome responses in SH-SY5Y neuroblastoma cells following
GM6 treatment (6, 24 and 48 h).
Results: We identified 2867 protein-coding genes with expression significantly altered by GM6 (FDR < 0.10). Early
(6 h) responses included up-regulation of Notch and hedgehog signaling components, with increased expression
of developmental genes mediating neurogenesis and axon growth. Prolonged GM6 treatment (24 and 48 h) altered
the expression of genes contributing to cell adhesion and the extracellular matrix. GM6 further down-regulated the
expression of genes associated with mitochondria, inflammatory responses, mRNA processing and chromatin
organization. GM6-increased genes were located near GC-rich motifs interacting with C2H2 zinc finger transcription
factors, whereas GM6-decreased genes were located near AT-rich motifs associated with helix-turn-helix
homeodomain factors. Such motifs interacted with a diverse network of transcription factors encoded by GM6-
regulated genes (STAT3, HOXD11, HES7, GLI1). We identified 77 ALS-associated genes with expression significantly
altered by GM6 treatment (FDR < 0.10), which were known to function in neurogenesis, axon guidance and the
intrinsic apoptosis pathway.
Conclusions: Our findings support the hypothesis that GM6 acts through developmental-stage pathways to
influence neuron survival. Gene expression responses were consistent with neurotrophic effects, ECM modulation,
and activation of the Notch and hedgehog neurodevelopmental pathways. This multifaceted mechanism of action
is unique among existing ALS drug candidates and may be applicable to multiple neurodegenerative diseases.
Keywords: Alzheimer’s disease, Amyotrophic lateral sclerosis, Extracellular matrix, Hedgehog, Huntington’s disease,
Neurodegenerative disease, Notch, Parkinson’s disease, RNA-seq, Transcriptome
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Background
Amyotrophic lateral sclerosis (ALS or “Lou Gehrig”
disease) is currently an incurable heterogeneous disease
of unknown etiology characterized by motor neuron
death leading to muscle paralysis [1]. The disease most
commonly occurs between the ages of 50 and 70 and is
twice as common in men compared to women [1]. It is a
unique disorder with deficits impacting both lower and
upper motor neurons, although either lower or upper
motor neuron dysfunction may be dominant for any one
patient [2]. The disease is ultimately fatal and death
typically occurs from respiratory failure in 1 to 6 years
[3]. At present, there is strong urgency among ALS
researchers and the patient community to develop
effective disease-modifying treatments. To this point,
however, clinical ALS management has emphasized sup-
portive measures (e.g., muscle relaxants) and working
closely with patients to preserve physiological function
(e.g., speech therapy) [4]. A wide range of novel treat-
ments based upon differing concepts have been
advanced in pre-clinical research and clinical trials,
although promising treatments have often failed to
demonstrate efficacy in late-phase clinical studies [5]. In
the United States, only three drugs are approved to
treat ALS, i.e., riluzole (Rilutek/Teglutik), edaravone
(Radicava/Radicut) and dextromethorphan HBr with
quinidine sulfate (Nuedexta). Nuedexta is narrowly
indicated for treatment of pseudobulbar affect and
bulbar symptoms [6], whereas riluzole and edaravone
are expected to improve disease course slightly
through different mechanisms, i.e., inhibition of
glutamate signaling and oxidative stress, respectively
[7, 8]. Unfortunately, no currently approved treatment
is expected to substantially alter disease course and
existing therapies appear to provide only marginal
symptomatic benefits [7, 8].
GM604 (GM6 or Alirinetide) is a cationic linear pep-
tide drug (799 Da) that has been developed by Genervon
Biopharmaceuticals (Pasadena, CA) [9, 10]. The peptide
consists of 6 amino acids (H-Phe-Ser-Arg-Tyr-Ala-Ar-
g-OH) representing a subunit of an endogenous 33
amino acid developmental-stage neurotrophic factor [11]
discovered in rat muscle and originally designated as
motoneuronotrophic factor 1 (MNTF1) [10, 12–14]. An
orthologous human protein was subsequently cloned
from a retinoblastoma cDNA library and analyzed to de-
termine its amino acid and cDNA sequences [10, 15].
The peptide drug GM6 is a 6 amino acid analog of the
MNTF1 active site that is able to cross the blood-brain
barrier [9] and appears to retain functional activity of
the full-length protein [16]. GM6 was shown to have
good drug-like properties based upon pharmacokinetic
profiling, with an estimated volume of distribution of
7.8 L/kg and minimum effective concentration of
1.6 mg/kg in humans [10, 17]. Although the half-life of
GM6 in human blood appears short (15 min), the drug
partitions readily into tissues where the half-life was
estimated to be 5.8 h, with an expected brain to plasma
concentration ratio of 1.65 [10]. Cellular uptake of GM6
has been directly demonstrated using quantitative im-
aging in induced pluripotent stem cell-derived GABAer-
gic neurons, and liver microsome assays further
indicated that its clearance rate was unaffected by
Riluzole [10]. Recently, a multi-center phase IIA clinical
trial was reported in which outcomes were compared
between 8 ALS patients receiving GM6 and 4 patients
receiving placebo for a 2 week period (ClinicalTrials.gov
identifier: NCT01854294) [18]. Although findings from
this study do not yet demonstrate efficacy, this trial has
demonstrated safety in ALS patients with encouraging
trends related to ALS Functional Rating Scale (ALSFRS),
forced vital capacity, and ALS biomarkers (e.g., TDP-43,
tau protein and SOD1) [18].
GM6 was developed as a multi-target drug believed to
trigger developmental-stage signaling pathways, which
may be largely dormant in the adult nervous system, but
can nonetheless function during the course of develop-
ment to enhance the survival and growth of neurons
[10, 12–14]. The regenerative capacities of the develop-
ing nervous system are well known, although the reason
why neurons lose this regenerative capacity after
development is not fully understood [19]. It has been
proposed that drugs designed to restore the develop-
mental gene expression program can provide an avenue
for developing neurodegenerative disease treatments
[19]. Consistent with this idea, GM6 is modeled upon a
neurotrophic factor protein able to promote neurite out-
growth, as demonstrated by trophic effects in transected
rat peripheral nerves and neuroprotection against toxic
agents in zebrafish [9]. GM6 was also reported to pro-
tect against ischemia in a reperfusion injury mouse
model [9]. This activity spectrum appears consistent
with a classical neurotrophic factor [11], and accord-
ingly, GM6 is expected to have a complex mechanism of
action potentially involving stimulation of multiple
receptors, signaling cascades and downstream gene
expression responses [20]. At present, however, exact
mechanisms of action (MOA) for GM6 have not been
determined. To develop hypotheses regarding the MOA
of investigational drugs such as GM6, transcriptome
profiling combined with bioinformatic analysis offers an
increasingly powerful approach that can provide a global
and objective view of a drug’s cellular effects [21–23].
This approach is especially well-suited to multi-target
drugs not developed to specifically interact with one
receptor, which may instead interact with multiple re-
ceptors with involvement of multiple signaling pathways
[20]. To understand the MOA for such drug products,
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transcriptome profiling provides a valuable tool that can
then be used to guide hypothesis-driven studies into one
or more drug mechanisms [21–23].
This study used whole transcriptome shotgun sequen-
cing (RNA-seq) to evaluate effects of GM6 on gene
expression in the SH-SY5Y neuroblastoma cell line. The
SH-SY5Y cell line was here chosen as a flexible model
system that has frequently been used in mechanistic
studies of ALS and other neurodegenerative diseases
[24–29]. We used RNA-seq as an unbiased methodology
to fully elucidate the set of genes exhibiting transcrip-
tional responses to GM6 stimulation, with the purpose
of identifying effector genes and their controlling
upstream signaling components (i.e., extracellular recep-
tors, signaling cascades, transcription factors (TFs) and
DNA response elements). Furthermore, given that GM6
is being actively investigated as an ALS therapeutic, we
evaluated its effects on the expression of ALS-associated
genes. Our findings allow us to propose mechanisms of
action to explain neurotrophic effects of GM6 and to
hypothesize ways in which these mechanisms may help
to preserve motor neuron function in ALS patients.
Materials & methods
SH-SY5Y neuroblastoma cells treated with GM6 for 6, 24
and 48 h
SH-SY5Y neuroblastoma cells were treated with GM6 or
water (CTL) with independent replicates at 6 h (n = 5
GM6, n = 3 CTL), 24 h (n = 5 GM6, n = 5 CTL) and 48 h
(n = 5 GM6, n = 5 CTL). Experiments were performed at
Sunny BioDiscovery laboratories (Santa Paula, CA).
GM6 hexapeptide was dissolved in cell culture medium
and tested at a final concentration of 1 mg/ml (1 mM)
for incubation times of 6, 24 or 48 h. Subconfluent
SH-SY5Y cells (Sigma, St. Louis, MO) were incubated
with GM6 in supplemented Eagle’s Minimum Essential/
F12 (1:1) Medium. Experiments were terminated after
microscopic observation of cells through Nikon (Tokyo,
Japan) Eclipse TS100 inverted microscope. RNA extrac-
tions were performed using the NucleoSpin RNA II kit
(Machery-Nagel; Bethlehem, PA) with the DNA diges-
tion step and robotic Qiacube (Qiagen, Valencia, CA)
workstation. Purified total RNA was assessed at 260 nm
and 280 nm with a NanoDrop Lite (Thermo Fisher
Scientific, Waltham, MA) spectrophotometer.
cDNA sequencing and data processing
The SH-SY5Y experiments generated 28 RNA samples
submitted for complementary DNA sequencing (University
of Michigan sequencing core facility). Sequencing was
performed with polyA-selected libraries using a 50 cycle
single end Illumina HiSeq 4000 platform. Raw fastq
files containing 50 base pair single-end non-stranded
reads with phred 33 quality score encoding were
provided by the core facility in January and February of
2017. Reads were combined across sequencing runs for
each of 28 sequencing samples. Cutadapt was used to
remove Illumina adaptor sequence (AGATCGGAA
GAGC) with maximum error rate (−e) of 5% and mini-
mum read length (−m) of 20 base pairs [30]. To remove
sequences mapping to rRNA, an initial tophat2 run
[31] was carried out using an edited gtf file specifying
only rRNA sequence coordinates for the UCSC
GRCh38/hg38 genome sequence, with 1 transcriptome
alignment reported per read (−g 1 --transcripto-
me-only) and disabling of coverage-based junction
search (−-no-coverage-search). Further analyses were
then performed using only the unmapped reads from
this preliminary tophat2 run. Cutadapt was used to
trim reads from the 3′ end using a quality score
threshold of 30 (−q) and minimum read length of 20.
Reads were then filtered using the Fastx toolkit
function fastq_quality_filter to retain only those reads
with quality scores above 30 for at least 50% of base
pairs (settings: -q 30 -p 50) [32]. Read tabulation and
quality analyses before and after filtering were
performed using FastQC [33] and the Fastx toolkit
function fastx_quality_stats [32].
After read filtering was complete, tophat2 was used to
map remaining reads to the UCSC GRCh38/hg38
transcriptome (−-transcriptome-only) with disabling of
read multi-mapping (−g 1) and coverage-based junction
search (−-no-coverage-search) [31]. Alignment files
generated from the tophat2 run for each sample were
indexed and sorted using samtools [34]. Read counts for
each GRCh38/hg38 human gene were tabulated using
htseq-count [35], with reads assigned to a gene only
when the alignment quality was greater than 10 (−a 10)
and when the read completely and unambiguously
overlapped a gene’s sequence (−m intersection-strict).
Fragments per kilobase of exon per million reads
mapped (FPKM) values and 95% confidence intervals
were calculated using Cufflinks with default settings
[36]. RNA-SeQC was used to calculate the proportion of
reads mapped to ribosomal genes, introns, exons and
intergenic sequences [37].
Following removal of reads mapping to rRNA and
reads with low quality scores, we obtained an average of
54.8 million reads per sample (Additional File 1A). Of
these, 97.8% on average mapped to the UCSC GRCh38/
hg38 genome sequence (Additional file 1 B), with 89.1%
assigned to intragenic sequences (Additional file 1 C) and
82.3% assigned to exons (Additional file 1 D). As expected
from our read filtering protocol, only 0.13% of reads on
average aligned to ribosomal RNA (Additional file 1 E).
An average of 14,299 protein-coding genes were detected
among the 28 samples (Additional file 1 F). Since
SH-SY5Y cells are derived from a female donor [25], we
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expected that few reads would map to chromosome Y.
Consistent with this, the average FPKM of protein-coding
genes on chromosome Y (0.10) was substantially less than
that of protein-coding genes on other chromosomes (aver-
age FPKM ≥11.7) (Additional file 2 A). Protein-coding
genes on chromosome Y had detectable expression in only
13% of samples on average (compared to ≥57% for other
chromosomes; Additional file 2 B), with residual mapping
to Y likely explained by low complexity DNA sequence or
paralogous regions on sex chromosomes [38]. The 28
samples were clustered based on the expression of
protein-coding genes and plotted with respect to the first
two principal component axes (Additional file 3). One
sample was identified as an outlier in both cluster and
principal component analyses (i.e., CTL-48 h-1;
Additional file 3). The same sample also differed notably
from others with a lower percentage of reads mapped
(89.3%) and fewer protein-coding genes with detectable
expression (13747) (Additional file 1 B and F). The sample
CTL-48 h-1 was therefore excluded and subsequent
analyses were based upon the 27 remaining samples.
Differential expression analyses
Differential expression analyses were performed to
compare expression of protein-coding genes between
GM6 and CTL cells at the 6, 24 and 48 h time points,
respectively. An additional differential expression
analyses was carried out to compare GM6 and CTL
treatments with samples combined across time points
(6–48 h). Differential expression analyses were per-
formed using only protein-coding genes with detectable
expression in at least 25% of the samples included in a
given GM6 vs. CTL comparison. For a given sample, a
gene was considered to have detectable expression if at
least 1 read mapped to its sequence and if the FPKM
95% confidence interval lower bound was greater than 0.
Applying these criteria, differential expression analyses
were performed for 13,736, 13,887 and 13,970
protein-coding genes at the 6, 24 and 48 h time points,
respectively. Likewise, differential expression analyses
were performed for 14,813 protein-coding genes in the
combined analysis (6–48 h).
The negative binomial model and likelihood ratio test
approach implemented in edgeR was used to evaluate
differential expression for each comparison (functions:
glmFit and glmLRT) [39, 40]. Read counts were normal-
ized using the weighted trimmed mean of M-values
method [41] with dispersions estimated using the
Cox-Reid (CR)-adjusted likelihood approach [40]. For
comparisons at a single time point (6, 24 or 48 h), a
design matrix was constructed based upon a single
treatment variable indicating whether samples belonged
to the GM6 or CTL treatment (full model). Likelihood
ratio tests were then performed by dropping the
treatment variable (reduced model) and comparing
likelihood between the two models (full vs. reduced). For
the combined analysis (6–48 h), the design matrix was
constructed with one treatment variable (GM6 vs. CTL)
and a second variable indicating treatment time (6, 24
and 48 h) (full model). Likelihood ratio tests were again
performed by dropping the treatment variable (reduced
model) and comparing likelihood between the two
models (full vs. reduced). To control the false discov-
ery rate, raw p-values generated from likelihood ratio
tests were adjusted using the Benjamini-Hochberg
method [42].
Gene ontology and pathway analyses
To characterize functional themes among differentially
expressed genes, we assessed identified genes for enrich-
ment of annotations with respect to multiple database
sources, including Gene Ontology (GO) [43], Kyoto
Encyclopedia of Genes and Genomes (KEGG) [44],
Reactome [45], and Disease Ontology [46]. Enrichment
of GO biological process, GO cell component and
KEGG terms was evaluated using the conditional hyper-
geometric test implemented in the R GOstats package
[47]. Enrichment of Reactome terms was evaluated using
the hypergeometric test implemented in the R Reacto-
mePA package [48], and enrichment of Disease Ontology
terms was evaluated using the hypergeometric test
implemented in the R DOSE package [49].
Analysis of DNA motifs enriched in regions upstream of
differentially expressed genes
DNA motifs enriched in 5000 base pair regions up-
stream of differentially expressed genes (DEGs) were
identified using semiparametric generalized additive lo-
gistic models (GAM) [50, 51]. These analyses modeled a
1–0 indicator response variable with value 1 if a gene
was identified as a DEG and value 0 if a gene had detect-
able expression but was not included among DEGs [50].
GAM models included two predictor variables x1 and x2,
where x1 was equal to the number of motifs identified in
5000 base pair upstream regions, and x2 was equal to
the length of sequence scanned excluding any coding
DNA sequence [50]. For each set of DEGs evaluated,
enrichment for a given motif was determined from the
z-statistic and p-value for the x1 indicator variable [50].
To control the false discovery rate, raw p-values gener-
ated from among the 2935 motifs were corrected using
the Benjamini-Hochberg method [42]. Analyses were
replicated for a filtered dictionary containing 2935
motifs. As described previously [51], motifs within this
dictionary were aggregated from a diverse set of sources
including the human protein-DNA interaction database
(hPDI) [52], Jaspar database [53], UniPROBE [54],
TRANSFAC [55] and the ENCODE project [56, 57]. All
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motifs included in the dictionary had been empirically
determined based upon interactions with one or more
human transcription factor or unconventional DNA
binding protein (e.g., ChIP-Seq, protein microarrays,
SELEX technology) [51].
Reverse transcription-polymerase chain reaction (RT-PCR)
RT-PCR was used to confirm differential expression for a
subset of genes identified as differentially expressed by
RNA-seq analysis. Analyses were performed using 48 h
time point samples (GM6, n = 5; CTL, n = 5). PCR reac-
tions were performed using Qiagen (Germantown, MD)
primer assays (CACNA1G: QT00043043; FAM65C:
QT00069671; TMEM255A: QT00061649), 5xAll-In-One
1st Strand cDNA Synthesis Mix (Bioland Scientific, Para-
mount, CA) and qPCR Master Mix (KiCqStart SYBR
Green qPCR ReadyMix, Sigma, St. Louis), and cycle
threshold values were generated using the iCycler iQ
Detection System (Bio-Rad, Hercules, CA). Relative gene
expression was evaluated using the 2-ΔΔCt method [58]
with normalization to heat shock protein 90 alpha family
class B member 1 (HSP90AB1) as a housekeeping gene.
Results
GM6 regulates the expression of 2867 protein-coding
human genes in SH-SY5Y neuroblastoma cells
RNA-seq was used to evaluate gene expression re-
sponses of protein-coding genes to GM6 hexapeptide
(Fig. 1a). Heatmap and cluster analyses showed good
agreement across time points with a minority of genes
exhibiting time-dependent responses (Fig. 1b). When
viewed in principal component space, effects of GM6
were partially consistent at each time point with better
agreement between the 24 and 48 h responses compared
to the 6 h response (Fig. 1c and d). Consistent with this,
expression responses were positively correlated across
time points, with good agreement between 24 and 48 h
responses (rs = 0.54) but relatively weaker agreement
between 6 and 48 h responses (rs = 0.28) (Fig. 1e).
Representation of global expression responses using
self-organizing maps (SOMs) also showed a congruent
pattern with respect to the 3 time points analyzed
(Fig. 1f and g). These global analyses indicated a
strong time-independent GM6 response with a com-
paratively minor but detectable time-dependent response.
For each time point, there was a trend towards
GM6-increased expression for genes located on chromo-
some 19 (FDR < 0.05; Figs. 1h – j). Expression of
genes located on chromosomes 18 and X tended to
be decreased by GM6, although this trend was signifi-
cant only for chromosome X at the 48 h time point
(FDR < 0.05; Fig. 1j).
Differentially expressed genes (DEGs) were next
identified by comparing gene expression in GM6- and
CTL-treated cells at each time point, respectively (6, 24
and 48 h; Additional file 4 A–I). To identify genes
exhibiting consistent trends across time, a second
differential expression analysis was also performed with
samples from all time points combined into a single
differential expression analysis (GM6 vs. CTL; 6–48 h;
Additional file 4 J–L). The largest number of differen-
tially expressed genes was identified with respect to the
earliest (6 h) treatment time point (Table 1). Without
applying a fold-change (FC) threshold, 2867 unique
protein-coding genes were altered by GM6 among the 3
time points (FDR < 0.10), which included 2119 genes
significantly altered in the combined 6–48 h analysis
(FDR < 0.10; Table 1). When analyses were repeated with
an added FC threshold (i.e., FDR < 0.10 with FC > 1.50 or
FC < 0.67), 812 unique GM6-regulated genes were iden-
tified, of which 295 remained significant when samples
from all time points (6–48 h) were included in the dif-
ferential expression analysis (Table 1). To verify
RNA-seq accuracy, we used RT-PCR to evaluate expres-
sion of 3 DEGs at the 48 h time point, including calcium
voltage-gated channel subunit alpha1 G (CACNA1G),
RIPOR family member 3 (FAM65C), and transmem-
brane protein 255A (TMEM255A). In each case, we ob-
served good agreement between RNA-seq and RT-PCR
results with consistent patterns of differential expression
(Additional file 5).
Notch pathway activation is an early response to GM6
(6 h) leading to up-regulation of extracellular matrix
genes (24–48 h)
Of genes significantly up-regulated by GM6 (FDR < 0.10),
some were strongly induced with expression elevated 2–
4-fold in GM6- versus CTL-treated cells (Fig. 2). Follow-
ing 6 h of GM6 treatment, the most strongly up-regulated
genes included KIAA1522, RAB3B member RAS onco-
gene family (RAB3B), and nectin cell adhesion molecule 2
(PVRL2) (Fig. 2a and g). Likewise, following 24 h of treat-
ment, strongly up-regulated genes included coronin 6
(CORO6), filamin C (FLNC) and tissue factor pathway
inhibitor 2 (TFPI2) (Fig. 2c and i). Late GM6 responses
following 48 h treatment included up-regulation of
transmembrane protein 255A (TMEM255A), cellular
retinoic acid binding protein 1 (CRABP1), and melanoma
cell adhesion molecule (MCAM) (Fig. 2e and k). For most
of these genes, expression responses were consistent
across the 3 time points (Fig. 2a, c and e).
Functional associations of genes up-regulated by GM6
were evaluated using multiple gene annotation sources,
including Gene Ontology [43], KEGG [44], Reactome [45]
and Disease Ontology [46] (Fig. 3 and Additional file 6).
Consistent with the idea that GM6 replicates the activity
spectrum of a developmental-stage protein, genes
up-regulated by GM6 were linked to developmental
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Fig. 1 (See legend on next page.)
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processes and multiple aspects of neuron growth (e.g.,
regulation of multicellular development, regulation of
neurogenesis, axon development, neuron differentiation,
generation of neurons). Development-associated genes
were prominently up-regulated by GM6 at the 6 h time
point (Fig. 3a) and many such “early response” genes were
associated with signaling (Fig. 3a), plasma membrane
(Additional file 6 A) and neural-ligand receptor inter-
action (Additional file 6 B). Pathways associated with
GM6-increased genes at 6 h included Notch, MAPK,
PI3K/AKT and EGFR (Additional files 6 B and C).
Up-regulated genes related to the Notch pathway encoded
ligands (JAG2), transmembrane receptors (NOTCH1,
NOTCH3) and transcriptional activating complexes
(MAML3) (Additional file 7).
Whereas genes up-regulated by GM6 at 6 h were
associated with signaling and the plasma membrane,
genes up-regulated at 24 and 48 h were most
frequently associated with cell adhesion, extracellular
matrix (ECM) and wound healing (Fig. 3b and c).
Consistent with this, genes up-regulated by GM6
following 24 and 48 h of treatment had structural
functions related to collagen trimer, collagen forma-
tion and collagen fibril assembly (Fig. 3b, c,
Additional file 6 E–L). Although fewer “late response”
up-regulated genes were associated with signaling,
genes increased at 24 and 48 h were associated with
the calcium signaling and MAPK pathways
(Additional file 6 F). Among genes increased by GM6
in the combined differential expression analysis (6–
48 h), there was additionally significant enrichment
with respect to the hedgehog signaling pathway (Add-
itional file 6 N). Up-regulated genes related to the
hedgehog pathway encoded ligands (DHH), kinases
(CSNK1G2), transcription factors (GLI1, GLI2) and
target genes (CCND1) (Additional file 8).
(See figure on previous page.)
Fig. 1 Global analysis of differential expression. (a) GM6 structure. (b) Hierarchical cluster analysis. FC estimates for 6777 protein-coding genes are
shown in the yellow-blue heat map (see scale) and by lines on the right (red = 6 h; green = 24 h; blue = 48 h). Genes were clustered using
average linkage and the Euclidean distance metric. The 6777 genes represent 50% of 13,554 genes included in all differential expression analyses
(selected as having the largest absolute FC estimate in any of the 4 differential expression analyses). (c) Principal component (PC) vectors (2-
dimensional). Arrows represent the effect of GM6. Arrow start points indicate the average PC coordinates of CTL samples and arrow end points
indicate the average PC coordinates of GM6 samples. (d) PC vectors (3-dimensional). The analysis in (c) was repeated using the first 3 PC axes.
(e) FC correlation between time points. Scatterplots compare FC estimates for the 3 possible pairwise time point comparisons. The color scale
indicates gene density. The spearman rank correlation is indicated in the lower right for each analysis. (f) Self-organizing map (SOM) color images.
A SOM was calculated based upon FC estimates observed for 12,562 protein-coding genes. The color scale indicates the average FC for genes
assigned to each SOM region. (g) Smoothed SOM surfaces. The SOMs from (f) are alternatively represented by smoothed surfaces with the
vertical axis corresponding to the average FC of genes assigned to each SOM region. Rotations are shown for each surface to provide alternative
viewing angles (45, 90, 135, 180 and 225 degrees). The smoothed surface was obtained by fitting a loess function using average FC as the
response variable and the other two axes as predictor variables. (h – j) Percent GM6-increased genes (FC > 1.00) per chromosome. Asterisks
indicate chromosomes with a significantly large (red) or small (blue) percentage of GM6-increased genes (FDR < 0.05; Fisher’s Exact Test)
Table 1 Differentially expressed genes (FDR < 0.10)
FC Threshold Comparison No. increased No. decreased Total
None 6 hours 678 480 1158
24 hours 726 297 1023
48 hours 446 107 553
6–48 hours 1320 799 2119
Pooleda 1724 1155 2867
FC > 1.50 or FC < 0.67 6 hours 228 115 343
24 hours 246 36 282
48 hours 285 29 314
6–48 hours 265 30 295
Pooleda 634 182 812
aPooled: Number of genes significantly altered by GM6 (FDR < 0.10) at the indicated FC threshold in any of the 4 comparisons performed (i.e., 6, 24, 48, or 6–48 h)
The table lists the number of differentially expressed genes (DEGs) significantly altered by GM6 in SH-5YSY neuroblastoma cells. All genes were significantly
altered at an FDR threshold of 0.10 and we tabulated the number of unique DEGs with and without an additional FC threshold (first column). Differential
expression analyses were performed with respect to each time point (6, 24 and 48 h). We additionally identified genes with evidence for a consistent differential
expression pattern with respect to each of the 3 time points (6–48 h) as well as genes differentially expressed in any of the 4 comparisons (pooled)
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Fig. 2 Top-ranked genes with expression most strongly altered by GM6. (a, c, e) GM6-increased genes. Heatmaps show genes most strongly
increased by GM6 at the (a) 6 h, (c) 24 h and (e) 48 h time points. (b, d, f) GM6-decreased genes. Heatmaps show genes most strongly decreased
by GM6 at the (b) 6 h, (d) 24 h and (f) 48 h time points. (g) KIAA1522 expression. (h) Synaptotagmin like 5 (SYTL5) expression. (i) Coronin 6
(CORO6) expression. (j) Regulator of G protein signaling 4 (RGS4) expression. (k) Transmembrane protein 255A (TMEM255A) expression. (l) TNF
receptor superfamily member 19 (TNFRSF19) expression. In (g) – (l), letters shown for each bar indicate results from post hoc treatment
comparisons (Fisher’s least significant difference), where treatments not sharing the same letter differ significantly (P < 0.05)
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Fig. 3 Gene Ontology (GO) biological process (BP) terms associated with GM6-increased genes. (a – d) Top-ranked GO BP terms. Figures list GO
BP terms most strongly enriched with respect to the GM6-increased DEGs (FDR < 0.10, FC > 1.50) identified at (a) 6 h, (b) 24 h, (c) 48 h and (d)
6–48 h. The number of GM6-increased genes associated with each GO BP term is listed in parentheses (left margin) and exemplar genes for each
term are listed in each figure. Statistical significance of enrichment (horizontal axis) was evaluated using a hypergeometric test. Labels associated
with some GO BP terms are abbreviated. (e – i) Heatmaps show GM6-increased genes associated with (e) generation of neurons (GO:0048699), (f)
signaling (GO:0023052), (g) regulation of multicellular organismal development (GO:2000026), (h) regulation of cell adhesion (GO:0030155) and (i)
wound healing (GO:0042060). The genes shown for each GO BP term were most strongly increased by GM6 at (e – g) 6 h, (h) 24 h or (i) 48 h
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GM6 represses the expression of genes linked to
inflammation, mitochondria, mRNA processing and
chromatin organization
Genes most strongly down-regulated by GM6 included
synaptotagmin like 5 (SYTL5), regulator of G protein
signaling 4 (RGS4), and TNF receptor superfamily
member 19 (TNFRSF19) following 6, 24 and 48 h of
treatment, respectively (Fig. 2b, d, f, h, j and l). Among
down-regulated genes, there was less consistency across
time points, particularly comparing the early 6 h to the
late 24 and 48 h responses (Fig. 2b, d and f). For some
genes, significant and opposite responses were observed
at different time points, e.g., clusterin (CLU), neural pre-
cursor cell expressed developmentally down-regulated 9
(NEDD9), MT-RNR2 like 3 (MTRNR2L3) and extracellu-
lar leucine rich repeat and fibronectin type III domain
containing 1 (ELFN1) (Fig. 2b, d and f).
At the early 6 h time point, GM6 decreased expression
of genes associated with the synthesis and metabolism of
the mitochondrial coenzyme ubiquinone (e.g., COQ2,
COQ7, COQ9; Fig. 4b). At multiple time points, genes
down-regulated by GM6 were frequently associated with
immunological functions (e.g., myeloid leukocyte activa-
tion, leukocyte proliferation, response to bacterium,
defense response, cytokine response, immune response
and cytokine receptor interaction; Figs. 4 and Additional
file 9). Genes decreased by GM6 were frequently associ-
ated with mRNA processing or transcription (e.g.,
spliceosome, RNA transport, RNA degradation, tRNA
processing, processing of pre-mRNA, transcription) as
well as processes related to 3-dimensional chromatin
structure (e.g., chromatin organization/modification,
protein acylation) (Additional file 9). Interestingly, while
GM6 decreased expression of genes associated with cell
death (Fig. 4d), GM6 also down-regulated the expression
of cell cycle-associated genes involved in diseases of
proliferation and cancer (Additional file 9 F and H). The
specific types of cancer associated with GM6-decreased
genes included stomach cancer, neuroblastoma, lung
cancer, pancreatic cancer, glioblastoma multiforme, as-
trocytoma and skeletal muscle cancer (Additional file 9).
Specific signaling pathways linked to GM6-decreased
genes included mTOR, VEGF and Fc epsilon RI
(Additional file 9 J: Figure).
GM6-increased genes are associated with GC-rich C2H2
zinc finger motifs and decreased genes are associated
with AT-rich helix-turn-helix homeodomain motifs
Our findings suggested that GM6 has diverse effects on
neurogenesis, collagen synthesis and immune/inflamma-
tory processes. We hypothesized that these effects are
mediated by signaling pathways linked to multiple recep-
tors and DNA transcription factors. We therefore evalu-
ated effects of GM6 on the expression of genes encoding
extracellular or intracellular receptors (Fig. 5a and b). At
multiple time points, GM6 increased expression of nerve
growth factor receptor (NGFR) and fibroblast growth
factor receptor like 1 (FGFRL1) (Fig. 5a, e and f) and
decreased expression of 5-hydroxytryptamine receptor
1E (HTR1E) and TNF receptor superfamily member 19
(TNFRSF19) (Fig. 5b, g and h). Likewise, genes encoding
transcription factors were altered by GM6 at multiple
time points (Fig. 5c and d). Among these, the most
strongly increased by GM6 included hes family bHLH
transcription factor 7 (HES7) and GLI family zinc finger
1 (GLI1) (Fig. 5i and j), while the most strongly de-
creased included KruppelAdd like factor 11 (KLF11) and
zinc finger protein 33B (ZNF33B) (Fig. 5k and l).
To characterize DNA binding sites interacting with
such factors, we screened 2935 DNA motifs to identify
those significantly enriched in regions upstream of
GM6-regulated genes. Each of the 2935 motifs had been
empirically determined based upon interactions with a
mammalian transcription factor or unconventional DNA
binding protein (uDBPs) [51]. At each time point, this
identified > 400 DNA motifs enriched with respect to
sequences upstream of GM6-increased genes, with fewer
motifs enriched with respect to GM6-decreased genes
(FDR < 0.05; Additional file 10). A clear pattern was that
GM6-increased genes were associated with motifs
having high GC content (Additional file 11), whereas
GM6-decreased genes were associated with motifs
having high AT content (Additional file 12). A motif
with consensus sequence 5-GAGGG/CCCTC-3 and
known to interact with zinc finger DHHC-type contain-
ing 5 (ZDHHC5) was either the top or second most
highly ranked motif associated with GM6-increased
genes at each time point (Additional file 11). For
GM6-decreased genes at 6 and 24 h, a motif with
consensus 5-TTGCAA/TTGCAA-3 and interacting with
GIT ArfGAP 2 (GIT2) was among the most enriched in
upstream regions (Additional file 12 A and B). In several
cases, motifs upstream of GM6-increased genes were
known to interact with proteins encoded by mRNAs for
which expression was altered by GM6 (Additional file 13
A and B), such as signal transducer and activator of
transcription 3 (STAT3), zinc finger matrin-type 2
(ZMAT2), annexin A11 (ANXA11) and MYCN
proto-oncogene bHLH transcription factor (MYCN)
(Additional file 13 C–F). Likewise, some motifs up-
stream of GM6-decreased genes interacted with proteins
encoded by mRNAs down-regulated by GM6, including
EEF1A lysine methyltransferase 3 (METTL21B), homeo-
box D11 (HOXD11), thyroid hormone receptor interac-
tor 10 (TRIP10) and CUGBP Elav-like family member 5
(CELF5) (Additional file 13 G–J).
Considering genes altered by GM6 in the combined
analyses (6–48 h), a large number of motifs were
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Fig. 4 Gene Ontology (GO) biological process (BP) terms associated with GM6-decreased genes. (a – f) Top-ranked GO BP terms. Figures list GO
BP terms most strongly enriched with respect to the GM6-decreased DEGs identified at (a, b) 6 h, (c) 24 h, (d, E) 48 h and (f) 6–48 h. The analyzed
DEGs were significant at the threshold of (a, c, d, f) FDR < 0.10 and FC < 0.67 or the less stringent threshold of (b, e) FDR < 0.10 and FC < 1.00 (*). The
number of GM6-decreased genes associated with each GO BP term is listed in parentheses (left margin) and exemplar genes for each term are listed
in each figure. Statistical significance of enrichment (horizontal axis) was evaluated using a hypergeometric test. Labels associated with some GO BP
terms are abbreviated. (g – j) Heatmaps show GM6-decreased genes associated with (g) oxidoreduction coenzyme metabolic process (GO:0006733),
(h) chromatin organization (GO:0006325), (i) ncRNA metabolic process (GO:0034660) and (j) biological regulation (GO:0065007). Genes shown for each
GO BP term were most strongly decreased by GM6 at 6 h
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significantly enriched in upstream regions of both
GM6-increased and GM6-decreased genes (GM6--
increased: 656 motifs; GM6-decreased: 498 motifs; FDR
< 0.05; Additional file 10). As noted above, motifs associ-
ated with GM6-increased genes were GC-rich, whereas
motifs associated with GM6-decreased genes were
AT-rich (Additional files 11, 12, 13). Consistent with
this, the motifs were also associated with different tran-
scription factor superfamilies, classes and families
(Figs. 6a and 7a) [59]. Motifs associated with
GM6-increased genes were most strongly associated
with TFs from the C2H2 class and zinc-coordinating
DNA-binding domain superfamily (Fig. 6b and c),
including many motifs belonging to the dispersed zinc
finger, 3 zinc finger Kruppel or bHLH-ZIP factor
families (Fig. 6d). In contrast, motifs associated with
GM6-decreased genes were most strongly associated
with TFs from the helix-turn-helix domain superfam-
ily and homeo class (Fig. 7b and c), with many motifs
belonging to the HOX-, NK- and SOX-related families
(Fig. 7d).
GM6 regulates the expression of ALS-associated genes
involved in neurogenesis, axon guidance and the intrinsic
apoptosis pathway
We hypothesized that GM6 may regulate the expression of
genes associated with ALS. We identified ALS-associated
genes from 9 database sources (Additional file 14 and
Fig. 8) [43, 44, 46, 60–66]. Among the 9 sources, 108 genes
were common to 3 or more databases and expressed at
levels sufficient to be included in differential expression
analyses. Of these 108 ALS-associated genes, expres-
sion of 29 (26.9%) was significantly altered by GM6
with respect to one or more time points, including 14
GM6-increased genes (FDR < 0.10) and 15 GM6-de-
creased genes (FDR < 0.10) (Fig. 8a, d and j). The over-
lap between the 108 ALS-associated genes and
GM6-increased genes was non-significant (P = 0.27);
however, overlap between ALS-associated genes and
GM6-decreased genes was significant (P = 9.38 × 10− 3)
(Fisher’s Exact test). Genes robustly associated with
ALS through 3 or more database sources thus
overlapped significantly with GM6-down-regulated
genes (Fig. 8a, d and j). Among such genes, we identi-
fied 3 that were at least marginally up-regulated (P <
0.05) at all time points (Fig. 8d), including B4GALT6,
ABCG1 (Fig. 8g), and NEFL (Fig. 8h).
These analyses were repeated with respect to genes
linked to ALS less robustly, i.e., based upon 1 or 2 of the
databases included in our analysis (Fig. 8b, c, e, f, k and l).
Among 195 genes linked to ALS by 2 databases and
expressed in our experiments, expression of 48 (24.6%)
had been significantly altered by GM6 (Fig. 8b, e and k).
The overlap was significant with respect to GM6-in-
creased genes (P = 3.30 × 10− 3) but not with respect to
GM6-decreased genes (P = 0.66) (Fisher’s Exact Test). We
identified 3 such genes significantly elevated by GM6
at all time points (Fig. 8e), including STON1, RET
and NEDD4L (Fig. 8i). Among 569 genes linked to
ALS by 1 database and expressed in our experiments,
expression of 116 (20.3%) had been significantly
altered by GM6 (Fig. 8c, f and l). Several of these
genes were significantly altered by GM6 at all time
points (e.g., NOTCH3, TGFB1, IGFBP5), although the
observed overlap was non-significant with respect to
GM6-increased and GM6-decreased genes (P ≥ 0.17;
Fisher’s Exact Test). These analyses show that genes
most robustly linked to GM6 (2 or 3+ database sources)
overlap significantly with GM6-regulated genes identified
by our analyses.
We next used gene annotation databases [43–45] to
better understand functions of ALS-associated genes
(2+ sources) significantly regulated by GM6 at one or
more time points (FDR < 0.10) (Additional file 15).
ALS-associated genes up-regulated by GM6 were
associated with developmental biology, regulation of
nervous system development, negative regulation of
apoptosis, positive regulation of neurogenesis, axon devel-
opment/guidance, neuron projection, and intermediate
filament cytoskeleton (Additional file 15 A, C, E and F).
ALS-associated genes down-regulated by GM6 were asso-
ciated with apoptosis, intrinsic pathway for apoptosis,
regulation of programmed cell death, apoptotic mitochon-
drial changes, mitochondrial matrix, positive regulation of
(See figure on previous page.)
Fig. 5 GM6-regulated genes encoding receptors and TFs. (a) Receptor-encoding genes most consistently up-regulated by GM6 across the 3 time
points (6–48 h). (b) Receptor-encoding genes most consistently down-regulated by GM6 across the 3 time points (6–48 h). (c) TF-encoding genes
most consistently up-regulated by GM6 across the 3 time points (6–48 h). (d) TF-encoding genes most consistently down-regulated by GM6
across the 3 time points (6–48 h). (e, f) Gene symbol clouds for genes encoding (e) receptors and (f) transcription factors. The size of each
symbol corresponds to the significance of p-values across the three time points (6, 24 and 48 h; red = GM6-increased; blue = GM6-decreased).
(g) Nerve growth factor receptor (NGFR) expression. (h) Fibroblast growth factor receptor like 1 (FGFRL1) expression. (i) 5-hydroxytryptamine
receptor 1E (HTR1E) expression. (j) TNF receptor superfamily member 19 (TNFRSF19) expression. (k) Hes family bHLH transcription factor 7 (HES7)
expression. (L) GLI family zinc finger 1 (GLI1) expression. (m) Kruppel like factor 11 (KLF11) expression. (n) Zinc finger protein 33B (ZNF33B)
expression. In (g) – (n), letters shown for each bar indicate results from post hoc treatment comparisons (Fisher’s least significant difference),
where treatments not sharing the same letter differ significantly (P < 0.05)
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chromatin modification and morphology modification
(Additional file 15 B, D, F and G).
Discussion
ALS is a debilitating and ultimately fatal neurodegenera-
tive disease for which few treatment options are
currently available. The peptide drug GM604 (GM6 or
Alirinetide) has been developed as a multi-target candi-
date ALS therapeutic with pharmacokinetic properties
similar to other small molecule drugs entering the
central nervous system [10]. This study used RNA-seq
to provide the first complete analysis of gene expression
responses to GM6, with the purpose of developing hy-
potheses regarding mechanisms of action. Our findings
demonstrate that GM6 significantly alters the expression
of > 2800 protein-coding genes in SH-SY5Y neuroblast-
oma cells, leading to expression responses consistent
with activation of multiple neurodevelopmental signaling
pathways (e.g., Notch and Hedgehog), increased abun-
dance of proteins contributing to the extracellular
matrix or cell adhesion (COL1A1, COL6A2, COL26A1),
and modulation of chromatin structure and a network of
transcription factors interacting with cis-regulatory ele-
ments (STAT3, HOXD11, HES7, GLI1). We identified 77
genes linked to ALS by multiple database sources that
were also regulated by GM6 at one or more time points
(e.g., TUBA4A, NEFL, NEDD4L, FGFR1, RET). Taken to-
gether, our findings support the hypothesis that GM6
enables neuron survival by restoring an embryonic-stage
gene expression program [19], while additionally
strengthening cell adhesion and an extracellular matrix
scaffold supporting the central and peripheral nervous
systems [67, 68]. This multi-target mechanism of action
is unique among existing ALS drug candidates and may
provide therapeutic benefit for ALS and multiple other
diseases characterized by progressive neuron loss (e.g.,
Alzheimer’s, Huntington’s and Parkinson’s diseases) [20].
In recent decades, more than 50 ALS randomized con-
trolled trials have been performed, but the majority of
these have failed to provide evidence of efficacy for the
investigational product [5, 69, 70]. This lack of progress
may be attributed, at least in part, to the multifactorial
nature of ALS [71] and the limitations of drugs designed
to narrowly target a single protein or cellular pathway
[20, 72]. In recognition of this, the peptide drug GM6
was not designed to regulate any one specific pathway,
but instead was developed to mimic the activity
spectrum of a neurotrophic factor expressed during
embryological development [10, 19]. Consistent with
this, our RNA-seq findings showed that GM6 increased
expression genes belonging to the Notch (JAG2,
NOTCH1, NOTCH3) and hedgehog (GLI1, DHH) neuro-
developmental pathways. Both pathways are critical medi-
ators of neurodevelopment with roles in morphogenesis,
cell-cell signaling, proliferation, differentiation and apop-
tosis [73]. The contributions of Notch and hedgehog to
ALS pathophysiology remains unclear. One study demon-
strated increased abundance of Notch proteins in spinal
cords from SOD1 G93A transgenic mice and NSC34 cells
transfected with mutant SOD1 [74]. However, hedge-
hog activation is cytoprotective against oxidative stress
[75–77], and hedgehog activity is repressed in CSF from
ALS patients [78]. While GM6 may activate Notch and
hedgehog independently, we favor a model involving
Notch-hedgehog crosstalk, in which GM6 up-regulates
Notch ligand and receptors with secondary activation
of hedgehog. This Notch-hedgehog axis was recently
supported by experiments showing declines in hedge-
hog signaling following Notch inhibition [79]. Interest-
ingly, this same study demonstrated that Notch
intracellular domain expression is decreased in spinal
cord motor neurons from transgenic mutant SOD1
mice, with the loss of intracellular domain expression
correlating with the onset of disease symptoms [79].
Concurrent with this, motor neurons from mutant SOD1
mice exhibited decreased expression of Gli family zinc fin-
gers Gli2 and Gli3 [79]. These studies suggest that mutant
SOD1 decreases activation of a Notch-hedgehog axis in
motor neurons, potentially indicating a mechanism con-
tributing to ALS pathogenesis. Our current data indicate
that this effect may be countered by GM6 treatment
through the up-regulation of ligands, receptors and tran-
scription factors associated with the Notch and hedgehog
pathways (Additional files 7 and 8).
The extracellular matrix provides a scaffold and micro-
environment that supports neurons and has an active
role in directing axon extension and growth [67, 68]. An
unexpected finding from this study was that prolonged
(See figure on previous page.)
Fig. 6 Variation and trends among DNA motifs enriched with respect to GM6-increased genes (6–48 h). (a) Motif cluster analysis. The 656 motifs
significantly enriched in regions upstream of GM6-increased genes (6–48 h, FDR < 0.05) were clustered based upon scores assigned to each
position weight matrix (PWM). Scores were calculated based upon the degree of correspondence between each PWM and a series of short k-mer
sequences (yellow-black heatmap). The 656 motifs were divided into groups based upon the cluster analysis, and representative sequence logos
for each group are shown below the heatmaps (see color scale). Black-red heatmaps show enrichment scores representing the degree to which
each motif resembles those from various TF superfamilies and classes. For each motif, enrichment scores represent log10-transformed p-values
derived from the test of whether motifs belonging to a given TF superfamily or class are overrepresented among the set of 300 similar “nearest
neighbor” motifs (Fisher’s Exact Test). (b) TF superfamilies most enriched among the 656 motifs. (c) TF classes most enriched among the 656
motifs. (d) TF families most enriched among the 656 motifs
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GM6 treatment (24–48 h) increased expression of genes
encoding collagen (COL1A1, COL6A2, COL26A1) and
other proteins localized to the ECM or functioning in
cell adhesion (TFIP2, MMP17, AGRN, MCAM). Poten-
tially, increased expression of such genes by GM6 may
have been mediated by up-regulation of transforming
growth factor beta 1 (TGFB1), which was significantly
increased by GM6 at all time points (Fig. 8f ) examined
and is a positive regulator of collagen synthesis [80].
These effects on the expression of genes encoding struc-
tural proteins, including many localized to skin, may be
expected under the hypothesis that GM6 signals through
developmental pathways that may be active prior differ-
entiation of neural and integumentary lineages from
ectoderm. The importance of ECM proteins in ALS is
not yet established, although an ECM abnormality was
suggested decades ago by the observation that ALS
patients do not develop bedsores as expected in immobi-
lized patients [81]. Since then, numerous studies have
found abnormal collagen and metalloproteinase levels in
the skin and spinal cord from ALS patients [82, 83], with
some studies demonstrating reduced collagen content
and smaller collagen fibrils in the skin and spinal cord
[84, 85], whereas other studies have demonstrated in-
creased dermal collagen in the sacral region [86]. These
and other findings have supported an ECM abnormality
affecting multiple tissues in ALS patients, although the
contribution of this to the disease pathogenesis is not
understood [82, 83]. Nonetheless, the up-regulation of
genes contributing to ECM and cell adhesion proteins
was a significant effect of GM6 in the current study,
which would be expected to bolster the scaffold
supporting axon growth [67, 68] or may otherwise
influence underlying collagen metabolism deficits in
ALS patients [84, 85].
Signaling pathways activated or inhibited by GM6
exert their effects by actively modulating downstream
gene transcription. This regulation can occur at multiple
levels through epigenetic modifications of chromatin
architecture to shift the euchromatin-heterochromatin
balance [87, 88], and through the control of transcrip-
tion factors interacting with cis-regulatory elements in a
sequence-specific fashion [89]. Our results provide
evidence that GM6 may alter gene transcription
through both mechanisms. Genes consistently down-
regulated by GM6 were frequently localized to the
nucleus (Additional file 9 M) and known to function in
chromatin organization and protein acetylation (Fig. 4b).
We additionally noted a strong pattern in which regions
upstream of GM6-increased genes were enriched with
GC-rich motifs interacting with zinc C2H2 transcription
factors, whereas regions upstream of GM6-decreased
genes were enriched with AT-rich motifs interacting
with helix-turn-helix homeodomain transcription
factors (Figs. 6, 7; Additional files 11 and 12). These
trends may indicate that GM6 partially regulates gene
expression through epigenetic mechanisms and in
particular by controlling methylation status of CpG
islands in promoters of GM6-increased genes identi-
fied by our analysis [90]. Notably, for instance, several
genes down-regulated by GM6 encoded methyltrans-
ferases such as METTL21B (also known as FAM119B
and EEF1AKMT3) and lysine methyltransferase 5B
(SUV420H1). Enrichment of GC-rich motifs upstream
of GM6-increased genes may also reflect modulation
of transcription factors targeting GC-rich motifs (e.g.,
STAT3, ZMAT2, MYCN), whereas enrichment of
AT-rich motifs upstream of GM6-decreased genes
may reflect modulation of factors targeting AT-rich
motifs (e.g., HOXD11, TRIP10, CEL5F). Altogether,
our findings provide evidence for a diverse network
of transcription factors regulated by GM6, including
developmental transcription factors associated with
Notch (HES7) (Fig. 5i) and hedgehog signaling (GLI1,
GLI2) (Fig. 5c). Regulation of this network combined
with epigenetic modifications of chromatin structure likely
contribute to the large number of GM6-regulated genes
identified by our study, consistent with the diverse
modes of gene regulation known to mediate neurode-
velopment [87, 88].
We investigated effects of GM6 on the expression of
genes previously associated with ALS to identify
disease-relevant processes and pathways altered as part
of the transcriptional response (Fig. 8). ALS-associated
genes altered by GM6 were functionally consistent with
other genes identified in our analysis and frequently re-
lated to neurogenesis, axon guidance and the intrinsic
apoptosis pathway (Additional file 15). Up-regulated
(See figure on previous page.)
Fig. 7 Variation and trends among DNA motifs enriched with respect to GM6-decreased genes (6–48 h). (a) Motif cluster analysis. The 498 motifs
significantly enriched in regions upstream of GM6-decreased genes (6–48 h, FDR < 0.05) were clustered based upon scores assigned to each
position weight matrix (PWM). Scores were calculated based upon the degree of correspondence between each PWM and a series of short k-mer
sequences (yellow-black heatmap). The 498 motifs were divided into groups based upon the cluster analysis, and representative sequence logos
for each group are shown below the heatmaps (see color scale). Black-red heatmaps show enrichment scores representing the degree to which
each motif resembles those from various TF superfamilies and classes. For each motif, enrichment scores represent log10-transformed p-values
derived from the test of whether motifs belonging to a given TF superfamily or class are overrepresented among the set of 300 similar “nearest
neighbor” motifs (Fisher’s Exact Test). (b) TF superfamilies most enriched among the 498 motifs. (c) TF classes most enriched among the 498
motifs. (d) TF families most enriched among the 498 motifs
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genes related to neurogenesis included neural precursor
cell expressed developmentally down-regulated 4-like E3
ubiquitin protein ligase (NEDD4L), fibroblast growth
factor receptor 1 (FGFR1), and ret. proto-oncogene
(RET). NEDD4L encodes a HECT domain E3 ubiquitin
ligase expressed in mouse embryonic neurons undergo-
ing proliferation and migration [91]. Similarly, FGFR1
encodes a member of the fibroblast growth factor recep-
tor family that functions in neuron migration [92] and is
highly expressed in the hippocampus as well as astro-
cytes and oligodendrocytes [93]. RET encodes a tyrosine
protein kinase family transmembrane receptor essential
for development of the enteric nervous system [94] and
has been found to mediate neurite extension in
SH-SY5Y cells [95]. Several ALS-associated genes regu-
lated by GM6 were associated with microtubule stability
(TUBA4A and NEFL), which is thought to be a key
factor underlying disease susceptibility and a promising
avenue for development of new ALS therapies [96]. For
example, TUBA4A has recently been associated with
ALS by genetic studies [97] and encodes an alpha-tubu-
lin protein integral to the microtubule cytoskeleton and
neuronal architecture [98]. Likewise, NEFL encodes a
neurofilament protein that contributes to microtubule
cytoskeleton organization and axonal transport (retro-
grade and anterograde). The regulation of these and
other ALS-associated genes by GM6 supports the hy-
pothesis that the drug is able to alter pathways involved
in the disease process and provides direction for future
translational studies.
This study used RNA-seq to provide the first complete
characterization of the transcriptional response to GM6
in the SH-SY5Y neuroblastoma cell line. We chose to
work with SH-SY5Y cells because they provide a
well-characterized model system frequently used in
mechanistic studies of ALS and other neurodegenerative
diseases [24–29]. Since these cells have a catecholamin-
ergic phenotype, they are especially well-suited for
studies of diseases in which dopaminergic cell death
plays a central role in disease pathology (e.g., Parkinson’s
disease) [25]. We expect that transcriptional responses
here observed in SH-SY5Y cells are, to some degree, rep-
resentative of those that would occur in diverse neuronal
cell types [24]. However, it should be noted that
SH-SY5Y cells are not motor neurons, which are the key
cell type that is lost in ALS to drive disease progression
[1, 3]. In future work, therefore, it will be valuable to
confirm our findings using other in vitro models
expected to reflect motor neuron physiology more faith-
fully, such as NSC-34 cells [99], primary motor neurons
[100], or stem cell-derived motor neurons [101]. Finally,
although many genes were identified as differentially
expressed in our study, confirmation of RNA-seq findings
with RT-PCR was performed only for a selected subset of
genes (i.e., CACNA1G, FAM65C and TMEM255A). The
agreement between RNA-seq and RT-PCR results
(Additional file 5) provides assurance that our findings are
robust, but it will nonetheless be valuable in future work
to provide similar RT-PCR confirmation for other genes
identified by our analysis [102].
The purpose of this study was not to evaluate efficacy
of GM6 as an ALS treatment, but rather to develop
hypotheses regarding its mechanism of action.
Altogether, our findings support the concept that GM6
replicates the activity of a neurotrophic factor targeting
developmental-stage pathways mediating neurogenesis.
In these respects, GM6 appears to provide a small mol-
ecule with properties that have long been pursued in
drug development for treatment of neurodegenerative
disease [19, 103–105]. We have highlighted ways in
which effects of GM6 may bolster neuron survival in the
setting of ALS, although it is interesting to note that
such effects may have therapeutic value for other dis-
eases characterized by loss of neuronal cell populations
(e.g., Alzheimer’s disease, Parkinson’s disease and Hun-
tington disease). Neurotrophic factors such as glial cell
line-derived neurotrophic factor (GDNF), brain-derived
neurotrophic factor (BDNF), and neurturin, for example,
all appear to protect against the striatonigral degener-
ation in Huntington’s disease [106–111]. The proposed
neurotrophic effects of GM6 thus represents a general
mechanism that, in the current era of single-target drug
(See figure on previous page.)
Fig. 8 ALS-associated genes regulated by GM6. (a) ALS-associated genes (3+ database sources) overlap with GM6-increased/decreased genes
(FDR < 0.10). (b) ALS-associated genes (2 database sources) overlap with GM6-increased/decreased genes (FDR < 0.10). (c) ALS-associated genes
(1 database source) overlap with GM6-increased/decreased genes (FDR < 0.10). In (a) – (c), GM6-increased genes include those increased by GM6
with respect to any of the 4 differential expression analyses (6, 24, 48, and/or 6–48 h; FDR < 0.10), and GM6-decreased genes include those
decreased by GM6 with respect to any of the 4 differential expression analyses (6, 24, 48, and/or 6–48 h; FDR < 0.10). (d) ALS-associated genes
(3+ sources). (E) ALS-associated genes (2 sources). (f) ALS-associated genes (1 source). In (D) – (f), heatmaps show the ALS-associated genes most
consistently altered by GM6 (6–48 h). (g) ATP binding cassette subfamily G member 1 (ABCG1) expression. (h) Neurofilament light (NEFL)
expression. (i) Neural precursor cell expressed developmentally down-regulated 4-like E3 ubiquitin protein ligase (NEDD4L) expression. In (g) – (i),
letters shown for each bar indicate results from post hoc treatment comparisons (Fisher’s least significant difference), where treatments not
sharing the same letter differ significantly (P < 0.05). (j) Gene symbol cloud for ALS-associated genes (3+ sources). (k) Gene symbol cloud for
ALS-associated genes (2 sources). (l) Gene symbol cloud for ALS-associated genes (1 source). In (j) – (l), the size of each symbol corresponds to
the significance of p-values across the three time points (6, 24 and 48 h; red = GM6-increased; blue = GM6-decreased)
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development [112], may provide a unique multi-target
drug candidate for treatment of ALS and multiple other
neurodegenerative conditions [103–105].
Conclusions
ALS is a devastating disease with only three approved
treatments available in the United States (riluzole,
edaravone, and dextromethorphan/quinidine sulfate)
[113]. No approved treatment significantly extends
survival for ALS patients. GM604 has good drug-like
properties [10, 17] and has demonstrated safety with
promising effects in a small phase IIA clinical study [18].
This study used RNA-seq to provide the first
complete analysis of gene expression responses to
GM6 using the SH-SY5Y neuroblastoma model. Our
findings demonstrate that GM6 alters the expression
of 2867 protein-coding genes, which were frequently
associated with developmental pathways linked to
neurogenesis. We observed significant up-regulation
of ligands, receptors and transcription factors associ-
ated with the Notch (NOTCH1, NOTCH3, JAG2,
HES7) and hedgehog signaling pathways (GLI1, GLI2,
DHH, WNT6). GM6 additionally altered the expres-
sion of genes associated with the extracellular matrix,
mitochondria, inflammatory responses, mRNA pro-
cessing and chromatin organization. We further char-
acterized a network of DNA motifs and associated
transcription factors potentially mediating transcrip-
tional responses to GM6. The 2867 genes altered by
GM6 includes 77 robustly associated with ALS by
multiple sources, which were functionally important for
neurogenesis, axon guidance and intrinsic apoptosis.
These findings provide insights into mechanisms of action
and support the hypothesis that GM6 acts upon develop-
mental signaling pathways to promote neurotrophic
effects and neuron survival. The regulation of multiple
pathways and > 2800 genes by GM6 suggests a multi-tar-
get mechanism of action, which may ultimately be needed
to treat and match the pathological complexity of ALS
and other neurodegenerative conditions [20].
Additional files
Additional file 1: Read mapping quality control (QC) assessment. (A)
Number of reads per sample after QC filtering steps. (B) Percentage of
reads mapped to the UCSC GRCh38/hg38 genome sequence. (C)
Percentage of reads mapped to annotated genes. (D) Percentage of
reads mapped to annotated exons. (E) Percentage of reads mapping to
ribosomal sequences. (F) Number of protein-coding genes with detectable
expression per sample. A gene was considered to have detectable
expression if at least 1 read mapped to the gene’s sequence and if the
FPKM 95% confidence interval lower limit was greater than 0. (TIF 1716 kb)
Additional file 2: Expression of protein-coding genes on each
chromosome. (A) Average FPKM among genes located on each
chromosome. (B) Average percentage of samples with detectable
expression among genes located on each chromosome. A gene was
considered to have detectable expression in a given sample if at least 1
read mapped to its sequence and if the FPKM 95% confidence interval
lower bound was greater than 0. In (A) and (B), the number of protein-
coding genes associated with each chromosome is listed in parentheses
(bottom margin). (TIF 690 kb)
Additional file 3: Cluster and principal component analyses. (A)
Hierarchical cluster analysis. The 28 samples were clustered based upon
the expression of 14,569 protein-coding genes with detectable expression
in at least 10 of the 28 samples (33%). Cluster analysis was performed using
average linkage and the Euclidean distance metric. (B) PC plot. The 28
samples are plotted with respect to the first two principal component axes.
The outlying sample “CTL-48 h-1” is indicated in the lower right corner. (C)
PC plot (without outlier). The outlying sample “CTL-48 h-1” was removed
and the 27 remaining samples are plotted with respect to the first 2
principal component axes. (TIF 1372 kb)
Additional file 4: Differential expression analyses. (A, D, G, J) Volcano
plots. Log10-transformed p-values (vertical axis) are compared to FC
estimates at each time point (horizontal axis). (B, E, H, K) MA plots. FC
estimates (vertical axis) are compared to the average abundance of each
gene (CPM = count per million, horizontal axis). (C, F, I, L) FPKM
scatterplots. The average log10-transformed FPKM estimate was
compared between GM6 and CTL treatments for all protein-coding gene
with detectable expression. In (A) – (L), each point represents an individual
gene. The number of DEGs identified in each analysis is indicated in the
upper margin (FDR < 0.10 with FC > 1.50 or FC < 1.50). (TIF 1342 kb)
Additional file 5: RT-PCR validation of RNA-seq findings. (A, B) Calcium
voltage-gated channel subunit alpha1 G (CACNA1G). (C, D) RIPOR family
member 3 (FAM65C/RIPOR3). (E, F) Transmembrane protein 255A
(TMEM255A). Panels (A), (C) and (E) show results from RNA-seq analyses
(FPKM). Letters shown for each bar indicate results from post hoc
treatment comparisons (Fisher’s least significant difference), where
treatments not sharing the same letter differ significantly (P < 0.05). Panels
(B), (D) and (F) show results from RT-PCR analyses (48 h time point).
Average relative gene expression is shown using heat shock protein 90
alpha family class B member 1 (HSP90AB1) as a reference gene. The
vertical axis for relative gene expression is arbitrary but normalized such
that average expression of the CTL treatment is equal to 1. In (B) and (D),
a one-tailed two-sample t-test was used to compare gene expression
between the GM6 and CTL treatment (*P < 0.05; p-value is listed in the
bottom margin). For panel (F), a one-tailed Wilcoxon rank sum test was
used to compare gene expression between GM6 and CTL treatments
(*P < 0.05; p-value is listed in the bottom margin; P = 0.064 based upon a
one-tailed two-sample t-test). (TIF 517 kb)
Additional file 6: Gene Ontology (GO) cell component (CC), Kyoto
Encyclopedia of Genes and Genomes (KEGG), Reactome and Disease
Ontology (DO) terms associated with GM6-increased genes. (A, E, I, M)
Top-ranked GO CC terms. Figures list GO CC terms most strongly
enriched with respect to the GM6-increased DEGs identified at (A) 6 h, (E)
24 h, (I) 48 h and (M) 6–48 h. (B, F, J, N) Top ranked KEGG terms. Figures
list KEGG terms most strongly enriched with respect to the GM6-
increased DEGs identified at (B) 6 h, (F) 24 h, (J) 48 h and (N) 6–48 h. (C,
G, K, O) Top-ranked Reactome terms. Figures list Reactome terms most
strongly enriched with respect to the GM6-increased DEGs identified at
(C) 6 h, (G) 24 h, (K) 48 h and (O) 6–48 h. (D, H, L, P) Top-ranked DO
terms. Figures list DO terms most strongly enriched with respect to the
GM6-increased DEGs identified at (D) 6 h, (H) 24 h, (L) 48 h and (P)
6–48 h. In (A) – (P), the analyzed DEGs were significant at the threshold
of FDR < 0.10 and FC > 1.50. The number of GM6-increased genes
associated with each term is listed in parentheses (left margin) and
exemplar genes for each term are listed in each figure. Statistical
significance of enrichment (horizontal axis) was evaluated using a
hypergeometric test. Labels associated with some terms are abbreviated.
(TIF 3144 kb)
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Additional file 7: KEGG Notch signaling pathway (hsa04330). Pathway
components are color-coded to indicate associations with GM6-increased
(red) or GM6-decreased (blue) genes. The color scale (bottom right)
reflects signed log100-transformed p-values, with positive values
indicating GM6-increased genes (red) and negative values indicated
GM6-decreased genes (blue). (TIF 881 kb)
Additional file 8: KEGG Hedgehog signaling pathway (hsa04340).
Pathway components are color-coded to indicate associations with
GM6-increased (red) or GM6-decreased (blue) genes. The color scale
(bottom right) reflects signed log100-transformed p-values, with positive
values indicating GM6-increased genes (red) and negative values
indicated GM6-decreased genes (blue). (TIF 1990 kb)
Additional file 9: Gene Ontology (GO) cell component (CC), Kyoto
Encyclopedia of Genes and Genomes (KEGG), Reactome and Disease
Ontology (DO) terms associated with GM6-decreased genes. (A, E, I, M)
Top-ranked GO CC terms. Figures list GO CC terms most strongly
enriched with respect to the GM6-decreased DEGs identified at (A) 6 h,
(E) 24 h, (I) 48 h and (M) 6–48 h. (B, F, J, N) Top ranked KEGG terms.
Figures list KEGG terms most strongly enriched with respect to the
GM6-decreased DEGs identified at (B) 6 h, (F) 24 h, (J) 48 h and (N)
6–48 h. (C, G, K, O) Top-ranked Reactome terms. Figures list Reactome
terms most strongly enriched with respect to the GM6-decreased DEGs
identified at (C) 6 h, (G) 24 h, (K) 48 h and (O) 6–48 h. (D, H, L, P)
Top-ranked DO terms. Figures list DO terms most strongly enriched with
respect to the GM6-decreased DEGs identified at (D) 6 h, (H) 24 h, (L)
48 h and (P) 6–48 h. In (A) – (D), the analyzed DEGs were significant at
the threshold of FDR < 0.10 and FC > 1.50. In (E) – (P), the analyzed DEGs
were significant at the less stringent threshold of FDR < 0.10 and FC <
1.00. The number of GM6-decreased genes associated with each term is
listed in parentheses (left margin) and exemplar genes for each term are
listed in each figure. Statistical significance of enrichment (horizontal axis)
was evaluated using a hypergeometric test. Labels associated with some
terms are abbreviated. (TIF 3066 kb)
Additional file 10: DNA binding sites associated with GM6-regulated
genes. Genes differentially expressed at each time point were analyzed to
identify DNA binding sites enriched in 5000 BP upstream regions. GM6-
increased (▲) and GM6-decreased (▼) genes were evaluated separately.
The table lists the number of enriched DNA motifs identified (FDR < 0.05)
from among 2935 screened (column 3). The protein interacting with the
most significant binding site is shown (column 4) with its DNA binding
site consensus sequence (column 5). Footnotes (a) – (h) list GM6-
regulated genes (FDR < 0.10) known to interact with one or more of the
significant motifs identified (ordered from most to least strongly altered
by GM6). Footnotes (i) – (p) list GM6-regulated target genes with the
greatest density of binding sites in the upstream region. (PDF 185 kb)
Additional file 11: DNA motifs enriched in sequences upstream of
GM6-increased genes. (A – D) Figures show motifs enriched in 5000 bp
regions upstream of genes increased by GM6 at (A) 6 h, (B) 24 h, (C) 48 h
and (D) 6–48 h (FDR < 0.10). Motif labels and consensus sequences are
listed in the left margin. Red font is used for motifs known to interact
with a protein encoded by a GM6-increased gene (P < 0.05), and blue
font used for motifs known to interact with a protein encoded by a
GM6-decreased gene (P < 0.05). Sequence logos for the top-ranked 12
motifs are shown for each time point. (TIF 2072 kb)
Additional file 12: DNA motifs enriched in sequences upstream of
GM6-decreased genes. (A – D) Figures show motifs enriched in 5000 bp
regions upstream of genes decreased by GM6 at (A) 6 h, (B) 24 h, (C)
48 h and (D) 6–48 h (FDR < 0.10). Motif labels and consensus sequences
are listed in the left margin. Red font is used for motifs known to interact
with a protein encoded by a GM6-increased gene (P < 0.05), and blue
font used for motifs known to interact with a protein encoded by a
GM6-decreased gene (P < 0.05). Sequence logos for the top-ranked 12
motifs are shown for each time point. (TIF 2023 kb)
Additional file 13: DNA motifs enriched in sequences upstream of
GM6-regulated genes and known to interact with a protein encoded by
a GM6-regulated gene (6–48 h). (A) Motifs associated with GM6-increased
genes. (B) Motifs associated with GM6-decreased genes. In (A) and (B),
red font is used for motifs known to interact with a protein encoded by
a GM6-increased gene (FDR < 0.10) and blue font is used for motifs
known to interact with a protein encoded by a GM6-decreased gene
(FDR < 0.10). Sequence logos for the top-ranked 12 motifs are shown for
each analysis. (C) Signal transducer and activator of transcription 3 (STAT3)
expression. (D) Zinc finger matrin-type 2 (ZMAT2) expression. (E) Annexin
A11 (ANXA11) expression. (F) MYCN proto-oncogene bHLH transcription
factor (MYCN) expression. (G) EEF1A lysine methyltransferase 3 (METTL21B)
expression. (H) Homeobox D11 (HOXD11) expression. (I) Thyroid hormone
receptor interactor 10 (TRIP10) expression. (J) CUGBP Elav-like family
member 5 (CELF5) expression. In (C) – (J), letters shown for each bar
indicate results from post hoc treatment comparisons (Fisher’s least
significant difference), where treatments not sharing the same letter differ
significantly (P < 0.05). (TIF 1637 kb)
Additional file 14: Gene databases used to identify ALS-associated
genes. The table lists the 9 databases used to identify ALS-associated
genes, the associated PubMed identifier, and the number of ALS-
associated genes identified from each source. The bottom rows list the
number of ALS-genes common to multiple database sources. (PDF 14 kb)
Additional file 15: Functional analysis of ALS-associated genes (2+
sources) with expression significantly altered by GM6 treatment (FDR <
0.10). (A, B) GO BP terms associated with (A) GM6-increased and (B) GM6-
decreased genes. (C, D) GO CC terms associated with (C) GM6-increased
and (D) GM6-decreased genes. (E, F) KEGG terms associated with (E)
GM6-increased and (F) GM6-decreased genes. (G, H) KEGG terms
associated with (G) GM6-increased and (H) GM6-decreased genes. For (A)
– (H), GM6-increased genes include those significantly increased by GM6
with respect to any of the 4 differential expression analyses performed
(FDR < 0.10; 6, 24, 48 and/or 6–48 h), while GM6-decreased genes include
those significantly decreased by GM6 with respect to any of the 4
differential expression analyses performed (FDR < 0.10; 6, 24, 48 and/or
6–48 h). The number of ALS-associated and GM6-increased/decreased
genes associated with each term is listed in parentheses (left margin) and
exemplar genes for each term are listed in each figure. Statistical significance
of enrichment (horizontal axis) was evaluated using a hypergeometric test.
Labels associated with some terms are abbreviated. (TIF 2066 kb)
Abbreviations
ALS: Amyotrophic lateral sclerosis; BP: Biological process; CC: Cell component;
CTL: Control treatment; DEG: Differentially expressed gene; ECM: Extracellular
matrix; FC: Fold-change; FDR: False discovery rate; FPKM: Fragments per
kilobase of exon per million reads mapped; GAM: Generalized additive
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GO: Gene ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes;
MOA: Mechanism of action; PC: Principal component; PWM: Position weight
matrix; QC: Quality control; SOM: Self-organizing map; TF: Transcription factor
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